ALKERMES | ALKS - Pre Tax Profit


ALKERMES reported $-61.93M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -93M 135M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Otsuka Holdings JPY 130.23B 54.96B Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026